secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeyondSpring Inc. (BYSI)
CIK:        0001677940
Form:       8-K
Filed at:   2026-10-06T20:30:15+00:00
Accession:  0001171843-26-006465
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 2.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

BeyondSpring closes sale of BeyondSpring Ltd. to Biolin for DUBLIN-4 data rights, $53.7M pro forma gain
--------------------------------------------------------------------------------

- Closed Sept. 30, 2026 sale of all BeyondSpring Ltd. shares, which indirectly held Bulin and SEED Technology, to Biolin Investment Limited; no cash consideration was paid.
- Consideration is noncash: Investor funds China portion of DUBLIN-4 Phase 3 trial of Plinabulin plus docetaxel in NSCLC; BYSI gets exclusive perpetual royalty-free license to Bulin Data.
- Clawback: if Bulin misses Target Enrollment within three years, Investor returns equity based on shortfall, including 100% of equity if shortfall is 90% or greater.
- Pro forma preliminary gain on Sale $53.7M; accumulated deficit improves to $(358.5)M from $(411.4)M, and total shareholders' deficit turns positive at $17.3M.
- Deconsolidates BeyondSpring Ltd. and SEED disposal groups; retains ~29% of SEED voting power via common and Series A-1 preferred, with right to elect two directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677940/000117184326006465/0001171843-26-006465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677940/000117184326006465/f8k_100626.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-006465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer